{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:56:52Z","timestamp":1761919012255,"version":"3.30.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2892,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>There is debate over the mortality and malignancy risk in people with primary biliary cirrhosis (PBC) and whether this risk is reduced by use of ursodeoxycholic acid. To investigate this issue, we identified 930 people with PBC and 9,202 control subjects from the General Practice Research Database in the United Kingdom. We categorized regular ursodeoxycholic acid as treatment with 6 or more prescriptions and nonregular treatment as less than 6. We found a 2.7-fold increase in mortality for the PBC cohort compared with the general population [adjusted hazard ratio (HR), 2.69; 95% CI, 2.35\u20133.09]. In those having regular ursodeoxycholic acid (43%), the mortality increase was 2.2-fold (HR, 2.19; 95% CI, 1.66\u20132.87) and in those not treated 2.7-fold (HR, 2.69; 95% CI, 2.18\u20133.33). This apparent reduction in mortality was not explained by less severe disease in the ursodeoxycholic acid\u2013treated group. The increased risk of primary liver cancer in ursodeoxycholic acid\u2013treated patients was 3-fold (HR, 3.17; 95% CI, 0.64\u201315.62), in contrast to an 8-fold increase in those not treated (HR, 7.77; 95% CI, 1.30\u201346.65).<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>We found that people with PBC had a 3-fold mortality increase when compared with the general population, which was somewhat reduced by regular treatment with ursodeoxycholic acid. However, the observed effect of ursodeoxycholic acid was not statistically significant. (HEPATOLOGY 2007.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21795","type":"journal-article","created":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T00:46:48Z","timestamp":1186620408000},"page":"1131-1137","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":59,"title":["Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis"],"prefix":"10.1097","volume":"46","author":[{"given":"Hannah","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Solaymani-Dodaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim R.","family":"Card","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-23-20241201","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholicacid therapy for primary biliary cirrhosis: a metaanalysis.","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"key":"R3-23-20241201","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Longterm effects of middose ursodeoxycholic acid in primary biliary cirrhosis: a metaanalysis of randomized controlled trials.","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R4-23-20241201","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.21404","article-title":"Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies.","volume":"44","author":"Sorensen","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R5-23-20241201","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"R6-23-20241201","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: followup for up to 28 years.","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"R7-23-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic acidtreated patients with primary biliary cirrhosis: results of a 10yr cohort study involving 297 patients.","volume":"101","author":"Ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R8-23-20241201","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2036.2005.02318.x","article-title":"Longterm ursodeoxycholic acid therapy for primary biliary cirrhosis: a followup to 12 years.","volume":"21","author":"Chan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-23-20241201","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(97)04248-7","article-title":"The UK General Practice Research Database.","volume":"350","author":"Walley","year":"1997","journal-title":"Lancet"},{"key":"R10-23-20241201","first-page":"40","article-title":"The General Practice Research Database: quality of morbidity data.","volume":"36-","author":"Hollowell","year":"1997","journal-title":"Popul Trends"},{"key":"R11-23-20241201","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/pds.2630010607","article-title":"Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom.","volume":"1","author":"Jick","year":"1992","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R12-23-20241201","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/bmj.302.6779.766","article-title":"Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.","volume":"302","author":"Jick","year":"1991","journal-title":"Br Med J"},{"key":"R13-23-20241201","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/thorax.55.10.864","article-title":"Adult height and cryptogenic fibrosing alveolitis: a casecontrol study using the UK general practice research database.","volume":"55","author":"Hubbard","year":"2000","journal-title":"Thorax"},{"key":"R14-23-20241201","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/pds.698","article-title":"Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease.","volume":"11","author":"Lewis","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-23-20241201","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1053\/j.gastro.2003.09.029","article-title":"Mortality in inflammatory bowel disease: a populationbased cohort study.","volume":"125","author":"Card","year":"2003","journal-title":"Gastroenterology"},{"key":"R16-23-20241201","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bmj.38169.486701.7C","article-title":"Malignancy and mortality in people with coeliac disease: population based cohort study.","volume":"329","author":"West","year":"2004","journal-title":"Br Med J"},{"key":"R17-23-20241201","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2006.09.012","article-title":"Fracture risk in people with primary biliary cirrhosis: a populationbased cohort study.","volume":"131","author":"SolaymaniDodaran","year":"2006","journal-title":"Gastroenterology"},{"key":"R21-23-20241201","first-page":"S2","article-title":"A comparison of the cause of death recorded in the General Practice Research Database with national mortality statistics in England and Wales.","volume":"13","author":"Shah","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R22-23-20241201","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(03)13808-1","article-title":"Primary biliary cirrhosis.","volume":"362","author":"Talwalkar","year":"2003","journal-title":"Lancet"},{"key":"R23-23-20241201","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/hep.510290501","article-title":"Hepatic and extrahepatic malignancies in primary biliary cirrhosis.","volume":"29","author":"Floreani","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R24-23-20241201","first-page":"1160","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virusrelated cirrhosis.","volume":"96","author":"Caballeria","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R25-23-20241201","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1053\/jhep.2002.33157","article-title":"Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis.","volume":"35","author":"Shibuya","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R26-23-20241201","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/gut.45.5.756","article-title":"Cancer risk in primary biliary cirrhosis: a study in northern England.","volume":"45","author":"Howel","year":"1999","journal-title":"Gut"},{"key":"R27-23-20241201","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.510290511","article-title":"Incidence of cancer in primary biliary cirrhosis: the Mayo experience.","volume":"29","author":"Nijhawan","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R28-23-20241201","first-page":"101","article-title":"Cancer risk in primary biliary cirrhosis: a populationbased study from Sweden.","volume":"20","author":"Loof","year":"1994","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21795","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200710000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:05:51Z","timestamp":1733058351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200710000-00023"}},"subtitle":["A population-based cohort study"],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21795","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}